News & Updates

Show Multimedia Only
Ustekinumab vs vedolizumab for older IBD patients: MACE not different, but mortality lower
Ustekinumab vs vedolizumab for older IBD patients: MACE not different, but mortality lower
28 Feb 2025 byJairia Dela Cruz

In the real-world treatment of older adults with inflammatory bowel disease (IBD), the cardiovascular safety of ustekinumab is similar to that of vedolizumab, with no significant difference in the risk of major adverse cardiovascular events (MACE). However, ustekinumab is associated with a reduced risk of all-cause mortality.

Ustekinumab vs vedolizumab for older IBD patients: MACE not different, but mortality lower
28 Feb 2025
Severe maternal morbidity up by fourfold in presence of CRC
Severe maternal morbidity up by fourfold in presence of CRC
27 Feb 2025 byJairia Dela Cruz

Pregnant women with colorectal cancer (CRC) face a considerably increased likelihood of severe maternal morbidity, including disseminated intravascular coagulation, acute respiratory distress syndrome, and hysterectomy, among others, according to a study.

Severe maternal morbidity up by fourfold in presence of CRC
27 Feb 2025
CKD management in primary care: Why use SGLT2i?
CKD management in primary care: Why use SGLT2i?
25 Feb 2025 byDr. Catherine Xiao-Rui Chen, Department of Family Medicine and Primary Healthcare, Kowloon Central Cluster, Hospital Authority; Prof. Per-Henrik Groop, University of Helsinki, Finland; Dr. Maggie Ma, Combined Renal Replacement Services, Queen Mary Hospital; Dr. Ting-Bong Chan, Jockey Club School of Public Health and Primary Care, Chinese University of Hong Kong

Primary care physicians, as patients’ first point of contact, play an important role in early detection and timely management of chronic kidney disease (CKD). Sodium-glucose cotransporter-2 inhibitors’ (SGLT2i) positive data in CKD trials have established their role as first-line therapy recommended by international and Hong Kong guidelines. At an industry-sponsored symposium organized by the Hong Kong College of Family Physicians, experts reviewed empagliflozin’s benefits in broad populations of CKD patients, and discussed how its early initiation may slow CKD progression and delay dialysis. Case reports were presented to illustrate real-world benefits of empagliflozin among patients managed in primary care in Hong Kong.

CKD management in primary care: Why use SGLT2i?
25 Feb 2025